Fjällskog ML - Search Results

1

Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Berglund A, Glimelius B, Bergh J, Brodin O, Fjällskog ML, Hagberg H, von Heideman A, Larsson R, Tholander B, de la Torre M, Aström G, Oberg K, Parö G, Nygren P. Berglund A, et al. Among authors: fjallskog ml. Med Oncol. 2002;19(3):151-9. doi: 10.1385/MO:19:3:151. Med Oncol. 2002. PMID: 12482125 Clinical Trial.

2

Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.

Fjällskog ML, Frii L, Bergh J. Fjällskog ML, et al. Eur J Cancer. 1994;30A(5):687-90. doi: 10.1016/0959-8049(94)90546-0. Eur J Cancer. 1994. PMID: 7915908

3

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Fjällskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Fjällskog ML, et al. Med Oncol. 2002;19(1):35-42. doi: 10.1385/MO:19:1:35. Med Oncol. 2002. PMID: 12025889

4

Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors.

Fjällskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Fjällskog ML, et al. Med Oncol. 2003;20(1):59-67. doi: 10.1385/MO:20:1:59. Med Oncol. 2003. PMID: 12665686 Clinical Trial.

5

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.

Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog ML, Bergh J, Karlsson MO. Sandström M, et al. Among authors: fjallskog ml. J Clin Oncol. 1996 May;14(5):1581-8. doi: 10.1200/JCO.1996.14.5.1581. J Clin Oncol. 1996. PMID: 8622075

6

Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer.

Koliadi A, Nilsson C, Holmqvist M, Holmberg L, de La Torre M, Wärnberg F, Fjällskog ML. Koliadi A, et al. Among authors: fjallskog ml. Acta Oncol. 2010 Aug;49(6):816-20. doi: 10.3109/02841861003691937. Acta Oncol. 2010. PMID: 20307242

7

Is Cremophor EL, solvent for paclitaxel, cytotoxic?

Fjällskog ML, Frii L, Bergh J. Fjällskog ML, et al. Lancet. 1993 Oct 2;342(8875):873. doi: 10.1016/0140-6736(93)92735-c. Lancet. 1993. PMID: 8104306 No abstract available.

8

Experience in treatment of metastatic pulmonary carcinoid tumors.

Granberg D, Eriksson B, Wilander E, Grimfjärd P, Fjällskog ML, Oberg K, Skogseid B. Granberg D, et al. Among authors: fjallskog ml. Ann Oncol. 2001 Oct;12(10):1383-91. doi: 10.1023/a:1012569909313. Ann Oncol. 2001. PMID: 11762808 Free article.

9

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Fjällskog ML, et al. Cancer. 2001 Sep 1;92(5):1101-7. doi: 10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v. Cancer. 2001. PMID: 11571721 Clinical Trial.

10

Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.

Norberg T, Jansson T, Sjøgren S, Mårtensson C, Andréasson I, Fjällskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J. Norberg T, et al. Among authors: fjallskog ml. Acta Oncol. 1996;35 Suppl 5:96-102. doi: 10.3109/02841869609083980. Acta Oncol. 1996. PMID: 9142977 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters